Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments
- 138 Downloads
An open 10-day study in which the therapeutic actions of Cereton were compared with those of piracetam was performed. Cereton was used in 40 patients (experimental group) at a dose of 1000 mg, while piracetam was used in 20 patients at a dose of 2000 mg; both agents were given as intravenous infusions in 200 ml of physiological saline on the background of antiparkinsonism agents. Patients’ status was evaluated using a complex of psychometric scales and neuropsychological tests, along with tools to assess the severity of the main symptoms of parkinsonism, side effects, and quality of life. Use of Cereton produced marked and moderate improvements in the state of cognitive functions more frequently than piracetam (40% and 25%, respectively), while the incidence of deterioration was lower (5% and 15%, p < 0.05). Cereton was very well tolerated by the patients: brief and short-term side effects were seen in only six patients (15%).
Key WordsParkinson’s disease cognitive impairments correction Cereton (choline alphoscerate)
Unable to display preview. Download preview PDF.
- 1.Zh. M. Glozman, Quantitative Assessment of Neuropsychological Study Data [in Russian], Moscow (1999).Google Scholar
- 2.V. V. Zakharov, I. V. Damulin, and N. N. Yakhno, “Cognitive impairments in patients with Parkinson’s disease,” Zh. Nevrol. Psikhiat., 1, 13–19 (2005).Google Scholar
- 3.O. S. Levin, “Mental disorders in patients with Parkinson’s disease and their correction,” in: Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 125–151.Google Scholar
- 4.O. S. Levin and N. V. Fedorova, Parkinson’s Disease [in Russian], Moscow (2006).Google Scholar
- 5.O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 85–91 (2008).Google Scholar
- 6.I. V. Litvinenko, Parkinson’s Disease [in Russian], Moscow (2006).Google Scholar
- 7.A. R. Luriya, Higher Cortical Functions in Humans and theirImpairments in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).Google Scholar
- 8.A. Yu. Panasyuk, An Adapted Variant of the Wechsler Test [in Russian], Research Institute Psychiatry, Moscow (1983).Google Scholar
- 11.R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers (2003).Google Scholar
- 15.S. Fahn and R. L. Elton, “Unified Rating Scale for Parkinson’s Disease,” in: Recent developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York, pp. 153–163.Google Scholar